Inclusion Criteria:  Informed consent signed; Newly confirmed EGFR Mutation-Positive NSCLC confirmed by histopathology except for cytology; Receiving or not receiving neoadjuvant treatment before surgery; Patients with stage I-III NSCLC undergo confirmed radical R0 resection;  Exclusion Criteria:  Patients who currently or have previously participated in any other anti-tumor clinical studies; Patients with NSCLC who have received any systemic anti-cancer therapy as the main treatment in the past. Cytotoxic therapy, targeted therapy (tyrosine kinase inhibitors or monoclonal antibodies) and immunotherapy included except for the use of neoadjuvant therapy; Patients who have received adjuvant therapy before enrollment. Patients with stage I-III NSCLC whose surgical resection cannot be confirmed. Patients assessed by the investigator as unfit for enrollment, such as neurological disorders or metabolic disorders, physical examination or laboratory examination suspected that the patient has a possible disease, or has contraindications to the use of study drugs, or has treatment-related complications High risk etc.